Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424097 | 1.00 | TP53 (0.45) | TP53TSHRSLC7A5ADAMTS4 | |
| SCHEMBL196163 | 1.00 | TP53 (0.45) | TP53TSHRSLC7A5ADAMTS4 | |
| Hydrochloric Acid SCHEMBL32661867 | 0.97 | TP53 (0.43) | TP53TSHRSLC7A5ADAMTS4 | |
| SCHEMBL28001459 | 0.81 | TP53 (0.43) | TP53TSHRSLC7A5ADAMTS4 | |
| SCHEMBL18921013 | 0.80 | TP53 (0.40) | TP53SLC7A5ADAMTS4 | |
| SCHEMBL14890392 | 0.80 | TP53 (0.40) | TP53SLC7A5ADAMTS4 | |
| SCHEMBL214942 | 0.80 | TP53 (0.40) | TP53SLC7A5ADAMTS4 | |
| SCHEMBL15023 | 0.80 | TP53 (0.40) | TP53SLC7A5ADAMTS4 | |
| SCHEMBL22383998 | 0.79 | TP53 (0.41) | TP53TSHRADAMTS4 | |
| SCHEMBL26449008 | 0.79 | TP53 (0.41) | TP53TSHRSLC7A5ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2016-08-25 | — | — | US | claimed |
| EP-3049428-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2016-08-03 | — | — | EP | claimed |
| WO-2015040235-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-03-26 | — | — | WO | claimed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240246986-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-5898029-A | PROMOTING SENSITIVITY OF NEURONAL CELL SYSTEMS TO NEUROTROPHIC FACTORS BY THE IMMUNOPHILIN LIGANDS FOR THERAPEUTIC APPLICATION IN DISEASES INVOLVING NEURAL DEGENERATION, NERVE DAMAGE BY PHYSICAL INJURY | THE JOHN HOPKINS UNIVERSITY (US) | 1999-04-27 | — | — | US | disclosed |
| WO-1998046247-A1 | SOLID PHASE SYNTHESIS OF IMMUNOSUPPRESSIVE AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998011908-A1 | COMBINATION THERAPY FOR TREATMENT OF ARTHRITIC DISEASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-26 | — | — | WO | disclosed |
| CN-1152941-A | Genes for synthesizing antipathogenic substances | CIBA GEIGY AG (CH) | 1997-06-25 | — | — | CN | disclosed |
| EP-0094412-B1 | MEDICAL PROCESS AND PREPARATION | JOHNSTON, Frederick Bertram (US) | 1987-07-22 | — | — | EP | disclosed |
| EP-0094412-A4 | MEDICAL PROCESS AND PREPARATION. | JOHNSTON FREDERICK BERTRAM | 1984-04-24 | — | — | EP | disclosed |
| EP-0094412-A1 | MEDICAL PROCESS AND PREPARATION. | JOHNSTON FREDERICK BERTRAM | 1983-11-23 | — | — | EP | disclosed |
| WO-1983001725-A1 | MEDICAL PROCESS AND PREPARATION | JOHNSTON, FREDERICK, BERTRAM | 1983-05-26 | — | — | WO | disclosed |
| US-4362745-A | Medical process and preparation | JOHNSTON FREDERICK B | 1982-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TP53 186/4885TSHR 4522/4885SLC7A5 2807/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885TSHR 4522/4885SLC7A5 2807/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885TSHR 4522/4885SLC7A5 2807/4885 |
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | TP53 4487/4885TSHR 2489/4885SLC7A5 1859/4885 |
| US-20240246986-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885TSHR 4522/4885SLC7A5 2807/4885 |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TP53 186/4885TSHR 4522/4885SLC7A5 2807/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TP53 186/4885TSHR 4522/4885SLC7A5 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.